HUTCHMED (China) Limited (HMDCF)

Market Cap	2.49B -6.5%
Revenue (ttm)	549.12M -8.8%
Net Income	17.88M -96.2%
EPS	0.02 -96.2%
Shares Out	n/a
PE Ratio	138.99
Forward PE	38.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.160
Previous Close	2.160
Day's Range	2.160 - 2.160
52-Week Range	2.160 - 3.660
Beta	0.45
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,790
• Stock Exchange: OTCMKTS
• Ticker Symbol: HMDCF

Financial Performance

In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 25, 2026

Data Sources Report a data error